Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cardiac fibroblasts become activated and differentiate to smooth muscle-like myofibroblasts in response to hypertension and myocardial infarction (MI), resulting in extracellular matrix (ECM) remodeling, scar formation and impaired cardiac function. cAMP and cGMP-dependent signaling have been implicated in cardiac fibroblast activation and ECM synthesis. Dysregulation of cyclic nucleotide phosphodiesterase (PDE) activity/expression is also associated with various diseases and several PDE inhibitors are currently available or in development for treating these pathological conditions. The objective of this study is to define and characterize the specific PDE isoform that is altered during cardiac fibroblast activation and functionally important for regulating myofibroblast activation and ECM synthesis. We have found that Ca2+/calmodulin-stimulated PDE1A isoform is specifically induced in activated cardiac myofibroblasts stimulated by Ang II and TGF-β in vitro as well as in vivo within fibrotic regions of mouse, rat, and human diseased hearts. Inhibition of PDE1A function via PDE1-selective inhibitor or PDE1A shRNA significantly reduced Ang II or TGF-β-induced myofibroblast activation, ECM synthesis, and pro-fibrotic gene expression in rat cardiac fibroblasts. Moreover, the PDE1 inhibitor attenuated isoproterenol-induced interstitial fibrosis in mice. Mechanistic studies revealed that PDE1A modulates unique pools of cAMP and cGMP, predominantly in perinuclear and nuclear regions of cardiac fibroblasts. Further, both cAMP-Epac-Rap1 and cGMP-PKG signaling was involved in PDE1A-mediated regulation of collagen synthesis. These results suggest that induction of PDE1A plays a critical role in cardiac fibroblast activation and cardiac fibrosis, and targeting PDE1A may lead to regression of the adverse cardiac remodeling associated with various cardiac diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 15×
“6c, Ang II stimulation markedly reduced Rap1-GTP, consistent with prior reports that Ang II and TGF-b inhibit Rap1 activity [69].”
BackgroundInfluentialTGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Wu, M., Melichian, D. S., de la Garza, M., Gruner, K., Bhattacharyya, S., Barr, L., Nair, A., Shahrara, S., Sporn, P. H. S., Mustoe, T. A., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090241 · Cited by 125
Cited by
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Role of miR-21 in the pathogenesis of atrial fibrosis
Adam, O., Löhfelm, B., Thum, T., Gupta, S. K., Puhl, S.-L., Schäfers, H.-J., Böhm, M., & Laufs, U. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0278-0 · Cited by 255
cAMP and Epac in the regulation of tissue fibrosis
Insel, P. A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L., Snead, A., Lu, D., & Aroonsakool, N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01847.x · Cited by 175
“Previous data have shown that targeting cAMP-PDEs, in particular PDE4 and PDE1, by family-specific inhibitors and siRNA can inhibit fibroblast activation, EMT and collagen synthesis (Dunkern et al., 2007; Kolosionek et al., 2009; Sachs et al., 2007; Miller et al., 2011).”
BackgroundIncreased afterload induces pathological cardiac hypertrophy: a new in vitro model
Hirt, M. N., Sörensen, N. A., Bartholdt, L. M., Boeddinghaus, J., Schaaf, S., Eder, A., Vollert, I., Stöhr, A., Schulze, T., Witten, A., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0307-z · Cited by 154
“The present findings indeed show that EHTs allow studying processes as complex as cardiac fibrosis, known to involve activated fibroblasts (myofibroblasts), endothelial cells, cardiomyocytes and monocytes [2, 24].”
Background
Metadata
- Authors
- Miller, C. L., Cai, Y., Oikawa, M., Thomas, T., Dostmann, W. R., Zaccolo, M., Fujiwara, K., & Yan, C.
- Venue
- Basic Research in Cardiology
- Published
- 2011-10-20
- Volume
- 106
- Issue
- 6
- Pages
- 1023-1039
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- OpenAlex
- W1974755741
- Cited by
- 113
- References
- 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. https://app.cochat.ai/papers/10.1007/s00395-011-0228-2
- The paper
- Miller, C. L., Cai, Y., Oikawa, M., Thomas, T., Dostmann, W. R., Zaccolo, M., Fujiwara, K., & Yan, C. (2011). Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Research in Cardiology. https://doi.org/10.1007/s00395-011-0228-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.